Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0YZPWM)
ADC Name
SGN-CD352A
Synonyms
SGN-CD352A
   Click to Show/Hide
Organization
Seagen (Top20 MNC) (Originator)
Drug Status
Phase 1 (discontinued)
Drug-to-Antibody Ratio
2
Antibody Name
H20F3ec
  Antibody Info 
Antigen Name
SLAM family member 6 (SLAMF6)
  Antigen Info 
Payload Name
PBD dimer
  Payload Info 
Payload Target
Human deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Val-Ala dipeptide linker
  Linker Info 
Conjugate Type
Reactive Cysteines
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
Disease Name Phase 1 Phase 2 Phase 3 Approved
Multiple myeloma
1 Trials
Clinical trial identifier
NCT02954796
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT02954796
PHASE1
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Eligible participants must have IMWG-defined multiple myeloma requiring systemic therapy, age ≥18 years, ECOG 0-1, life expectancy >3 months, ≥2 prior lines of therapy (including IMiD and PI), measurable disease, adequate organ function, and negative pregnancy test. Key exclusions include recent malignancies (past 3 years), active CNS disease, severe infections, HIV/HBV/HCV positivity, prior allogeneic transplant, significant pulmonary/cardiovascular comorbidities, or pregnancy/breastfeeding.

   Click to Show/Hide
Administration Dosage
On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
Related Clinical Trial
NCT Number NCT02954796  Clinical Status PHASE1
Clinical Description Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Primary Endpoint
The study assesses safety through comprehensive evaluation of adverse events (type, incidence, severity, seriousness, and relatedness) monitored for 1 month post-treatment, along with dose-limiting toxicities during the first 28-day cycle.
Other Endpoint
Efficacy outcomes include overall survival, progression-free survival, duration of response (both objective and complete), and response rates (ORR/CR) tracked for approximately 3 years, complemented by immunogenicity analysis (antitherapeutic antibodies) and pharmacokinetic profiling of SGN-CD352A and metabolites over the same period.
References
Ref 1 A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma